scPharmaceuticals Inc. (SCPH) News
Filter SCPH News Items
SCPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SCPH News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SCPH News From Around the Web
Below are the latest news stories about SCPHARMACEUTICALS INC that investors may wish to consider to help them evaluate SCPH as an investment opportunity.
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial ResultsPreliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over Q4 2023 at the mid-point of the range Fourth quarter 2024 Gross-to-net (GTN) discount expected to be in the range of 18% to 19% Preliminary unaudited full year 2024 net revenue expected to be approximately $36.2 million to $36.5 million, compared to $13.6 million for full year 2023 BURLINGTON, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. |
scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shift From Loss To ProfitWith the business potentially at an important milestone, we thought we'd take a closer look at scPharmaceuticals Inc.'s... |
Earnings Update: scPharmaceuticals Inc. (NASDAQ:SCPH) Just Reported And Analysts Are Trimming Their ForecastsAs you might know, scPharmaceuticals Inc. ( NASDAQ:SCPH ) last week released its latest third-quarter, and things did... |
scPharmaceuticals Third Quarter 2024 Earnings: Misses ExpectationsscPharmaceuticals ( NASDAQ:SCPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$10.0m (up 164% from 3Q... |
scPharmaceuticals Inc (SCPH) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...scPharmaceuticals Inc (SCPH) reports a 24% revenue increase and strategic advancements, despite facing significant net losses and operational hurdles. |
ScPharmaceuticals, Inc. (SCPH) Reports Q3 Loss, Lags Revenue EstimatesscPharmaceuticals (SCPH) delivered earnings and revenue surprises of -23.33% and 7.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business UpdateGenerated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, Novembe |
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
scPharmaceuticals to Announce Third Quarter 2024 Financial Results on Wednesday, November 13, 2024Management to host conference call and webcast, after-market on November 13, 2024, at 4:30 p.m. ETBURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the third quar |
scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 2024Webinar to focus on a nephrologist’s perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney diseaseBURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it will host a KOL webinar focused on |